

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Xuanzhu Biopharmaceutical Co., Ltd.

軒竹生物科技股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2575)

VOLUNTARY ANNOUNCEMENT
FIRST PATIENT ENROLLED IN PHASE III CLINICAL TRIAL OF
ANAPRAZOLE SODIUM FOR
HELICOBACTER PYLORI ERADICATION

The board of directors (the “**Board**”) of Xuanzhu Biopharmaceutical Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the first patient has been successfully enrolled recently in the Phase III clinical study of the Group’s independently developed innovative drug Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei (安久衛®)) as part of a bismuth-containing quadruple therapy for the eradication of Helicobacter pylori (“**Hp**”), marking that this key registration clinical study has officially entered the substantive execution stage.

This Phase III clinical trial is a multi-centre, randomized, double-blind, double-dummy, active-drug parallel-controlled trial, which plans to enroll 556 adult subjects for Hp positive. Using bismuth-containing quadruple therapy containing esomeprazole magnesium as the active control, the trial aims to evaluate the efficacy, safety and population pharmacokinetic characteristics of bismuth-containing quadruple therapy containing anaprazole sodium administered continuously for 14 days for Hp eradication. The primary endpoint is the Hp eradication rate confirmed by ¹³C-urea breath test (“**¹³C-UBT**”) on day 28 after the completion of treatment.

Hp is a Gram-negative microaerophilic pathogenic bacterium closely associated with a variety of gastric diseases, including gastric ulcer, chronic progressive gastritis and gastric cancer. According to Frost & Sullivan, the infection rate of Hp in China is approximately 44%, and the market size of drugs for the treatment of Hp infection continues to expand. The market size reached RMB5.5 billion in 2024, and is projected to increase to RMB6.8 billion in 2029 and reach RMB12.6 billion in 2035.

Following the approval to initiate the Phase III clinical trial for Hp eradication indication by the Center for Drug Evaluation (“CDE”) of the National Medical Products Administration (“NMPA”) of the People’s Republic of China (“China”) in April 2026, the first patient was enrolled rapidly, which fully demonstrates the efficient execution capability of the Company’s clinical development team and marks that the project has officially entered the key stage of clinical implementation. If this indication is successfully approved for marketing in the future, it is expected to further expand the target patient population of anaprazole sodium, accelerate the product’s market penetration, and create a new performance growth driver for the Company in the digestive field.

ABOUT ANAPRAZOLE SODIUM ENTERIC-COATED TABLETS

Anaprazole Sodium Enteric-coated Tablets (trade name: An Jiu Wei (安久衛®)) was approved for marketing by the National Medical Products Administration of China in June 2023 for the treatment of patients with duodenal ulcer. Anaprazole Sodium features an innovative structural design with characteristics including non-enzymatic plus multi-enzymatic metabolism and balanced intestinal-renal dual-channel excretion, with only 3.5% metabolized through CYP2C19, making it unaffected by CYP2C19 gene polymorphism. Compared with previous generations of proton pump inhibitors, Anaprazole Sodium has lower risk of drug-drug interactions, making it a safer choice for patients on multiple medications and those with renal impairment, and is a proton pump inhibitor more suitable for the Chinese population. As a Class 1 innovative drug in China, Anaprazole Sodium fills the gap in domestically developed proton pump inhibitors, bringing treatment options with both superior efficacy and safety to Chinese patients.

This announcement is a voluntary announcement made by the Company for the purpose of keeping its shareholders and potential investors informed of the Group’s latest business developments and does not contain any advertisement or intention regarding the use of any drugs, surgical equipment, treatments, or oral products.

By order of the Board
Xuanzhu Biopharmaceutical Co., Ltd.
Ms. Xu Yanjun

Chairperson of the Board and executive Director

Hong Kong, 21 June, 2026

As of the date of this announcement, the Board comprises (i) Ms. Xu Yanjun and Dr. Shih Cheng-Kon as executive Directors; (ii) Ms. Li Huiying, Mr. Yu Lifeng and Ms. Chen Yanling as non-executive Directors; (iii) Ms. Yue Xin as employee representative Director; and (iv) Mr. Liu Shuo, Ms. Wang Yu and Mr. Fan Chi Chiu as independent non-executive Directors.